ETF Securities launches CURE ETF

ETF Securities has launched its new CURE exchange-traded fund (ETF) on the Australian Securities Exchange (ASX), which will offer investors exposure to healthcare biotechnology companies.

CURE would follow the S&P Biotechnology Select Industry Index, which according to the company, achieved annual growth of 21.9 per cent in Australian dollar terms over the five years to 31 October 2018.

Additionally, the fund would hold more than 120 biotechnology firms in its portfolio, with a focus on small and mid-cap companies. The fund’s fee would stand at 0.45 per cent.

Related News:

Head of ETF Securities Australia, Kris Walesby, said: “This is very much a high growth-oriented product.”

“Given the mainly mid- and small-cap profiles of the constituent stocks, we’d expect to see profitable M&A activity. We are pleased to be adding CURE to our ‘Future Present’ series of ETFs.”

Walesby also stressed that there would be demanding filters to be met before a company can be included in CURE, with companies needing to meet S&P Dow Jones Indices’ Float Adjustment liquidity requirements.

Related Content

Janus Henderson reports lower revenue in Q3

Janus Henderson (JHG) has reported lower adjusted revenue in the third quarter of 2018, down from US$477.7 million in Q2 to US$468.9 million in Q3, af...Read more

Natixis launches global private equity manager

Natixis Investment Managers has announced the launch of Flexstone Partners, a global private equity manager, which together with its existing private ...Read more

UBS AM expands with two new partnerships

UBS Asset Management has announced its two new partnerships with CBRE Clarion and Yarra Capital Management, which will include management of its UBS b...Read more



Add new comment